Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...

1 King’s College London Faculty of Life Sciences and Medicine, London, UK Introduction Crohn’s disease (CD) is a chronic, immune-mediated inflammatory bowel disease (IBD), presenting with symptoms of ...

Fat—adipose tissue—is more complicated than might be thought. Once considered just a bag of calories, scientists now know that fat doesn’t just squirrel away energy, it also sends and receives ...

Fat is more complicated than we thought. Once considered just a bag of calories, scientists now know that our fat — aka adipose tissue — doesn’t just squirrel away energy; it also sends and receives ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Background Crohn’s disease (CD) is a chronic inflammatory disease involving the whole digestive tract, which is destructive and progressive, and can lead to intestinal injury and disability. As one of ...

Although a growing spectrum of biologic therapies have proven effective in managing inflammation and inflammatory strictures in Crohn's disease (CD), treatment options remain limited for fibrotic ...

The majority of patients with Crohn's disease (CD) are likely to develop symptomatic intestinal strictures, which are a major indication for surgery. Currently, there are no specific anti-stricture ...

Achieving complete mucosal healing, instead of partial improvement, may be a more effective therapeutic target in altering the disease course of CD. Patients with Crohn disease (CD) who achieved ...